Ercros, S.A. (ECR.MC)
- Previous Close
3.5350 - Open
3.5350 - Bid 3.5350 x --
- Ask 3.5450 x --
- Day's Range
3.5300 - 3.5450 - 52 Week Range
2.2600 - 4.3650 - Volume
49,197 - Avg. Volume
194,924 - Market Cap (intraday)
322.77M - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
11.39 - EPS (TTM)
0.3100 - Earnings Date Apr 30, 2024
- Forward Dividend & Yield 0.15 (4.24%)
- Ex-Dividend Date Jun 26, 2023
- 1y Target Est
--
Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain. It operates through three segments: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment produces ammonia, bioplastics, caustic potash and soda, chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers and polychloride. This segment's products are used as intermediates in other industrial processes to purify and treat drinking and waste water; treat and maintain swimming pool water; bleach fabrics and paper; produce solvents, detergents, and strippers; manufacture printing inks and coloring; to produce compound feed and in cooling equipment. The Intermediate Chemicals segment provides formaldehyde, glues and resins, molding compunds, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate for manufacturing of particle, and decorative laminates and plywoods, as well as resins, paints, and varnishes in the furniture and decoration industry; sockets and switches in the electrical components sector; and tableware, and health and packaging items in the textile tanning industry. The Pharmacy division engages in the production of raw materials and pharmaceutical intermediate products from antibiotic, cholesterol-lowering, anti-ulcer, and anti-fungal agents. This segment's products include amlodipine besylate, azithromycin, clarithromycin, erythromycins, famotidine, fosfomycin calcium and sodium, fosfomycin trometamol, and fusidic acid. The company is also involved in exporting activities. Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain.
www.ercros.esRelated News
Performance Overview: ECR.MC
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ECR.MC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ECR.MC
Valuation Measures
Market Cap
323.23M
Enterprise Value
434.32M
Trailing P/E
11.22
Forward P/E
17.67
PEG Ratio (5yr expected)
3.61
Price/Sales (ttm)
0.46
Price/Book (mrq)
0.89
Enterprise Value/Revenue
0.61
Enterprise Value/EBITDA
9.03
Financial Highlights
Profitability and Income Statement
Profit Margin
3.80%
Return on Assets (ttm)
-0.25%
Return on Equity (ttm)
7.96%
Revenue (ttm)
726.29M
Net Income Avi to Common (ttm)
28.8M
Diluted EPS (ttm)
0.3100
Balance Sheet and Cash Flow
Total Cash (mrq)
39.15M
Total Debt/Equity (mrq)
36.15%
Levered Free Cash Flow (ttm)
14.13M
Company Insights: ECR.MC
ECR.MC does not have Company Insights